Evidence map›Paper›PMID 34950525›Full record

ArticleJournal of AIDS & clinical research2021

Molecular Docking-Based Screening for Novel Inhibitors of the Human Immunodeficiency Virus Type 1 Protease that Effectively Reduce the Viral Replication in Human Cells.

Carla Mavian, Roxana M Coman, Xinrui Zhang, Steve Pomeroy, David A Ostrov, Ben M Dunn, John W Sleasman, Maureen M Goodenow

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of AIDS & clinical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Carla MavianDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Roxana M ComanDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Xinrui ZhangDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Steve PomeroyDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
David A OstrovDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Ben M DunnDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.
John W SleasmanPediatric Allergy, Immunology, and Pulmonary Medicine, Duke University, Durham, NC 27710, USA.
Maureen M GoodenowOffice of AIDS Research, National Institutes of Health, USA.
University of Florida · USDuke University · USOffice of AIDS Research · US

Funding

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASER01AI028571 · NIAID · UNIVERSITY OF FLORIDA · PI DUNN, BEN M. · 1989 to 2004
$1.3M
NIAID NIH HHS R01 AI028571
6 · The paper itself

Abstract

Therapeutic pressure by protease inhibitors (PIs) contributes to accumulation of mutations in the HIV type 1 (HIV-1) protease (PR) leading to development of drug resistance with subsequent therapy failure. Current PIs target the active site of PR in a competitive manner. Identification of molecules that exploit non-active site mechanisms of inhibition is essential to overcome resistance to current PIs. Potential non-active site HIV-1 protease (PR) inhibitors (PI) were identified by in silico screening of almost 140,000 molecules targeting the hinge region of PR. Inhibitory activity of best docking compounds was tested in an

Indexed as

HIV-1Molecular dockingNon-active site targetingProtease inhibitors

Identifiers

PMID34950525
PMCPMC8694022
OpenAlexW4287484848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.